Sanofi

Granite Bio is a biotechnology company focused on developing novel monoclonal antibody therapies targeting inflammatory, autoimmune, and fibrotic disorders.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in first-in-class immunotherapy drug candidates that target receptors and pathways controlling innate immunity. Its product pipeline includes Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma. Other notable candidates include IPH5201, a CD39-targeting antibody in Phase I trials, and IPH5301, a CD73-blocking antibody in preclinical development. Innate Pharma utilizes its proprietary ANKET platform to create innovative therapies and has established licensing and collaboration agreements with major pharmaceutical companies. Founded in 1999, Innate Pharma continues to advance its mission of harnessing the innate immune system to improve cancer treatment outcomes.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

AdvanCell is a clinical-stage company developing novel radiopharmaceuticals for cancer treatment. It specializes in attaching alpha-emitting isotopes to molecules that deliver cytotoxic radiation directly to tumors, aiming to provide safe and effective therapies for multiple cancer types.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Resalis Therapeutics focuses on treating metabolic diseases by targeting key regulators of pathways related to obesity and fatty liver disease. Its flagship program, RES-010, is a non-coding RNA drug modality designed for long-term weight loss and reduced hepatic steatosis.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Vicore Pharma is a clinical-stage pharmaceutical company focused on severe lung diseases. It develops medicines that act through the angiotensin II type 2 receptor, with its lead candidate C21 currently in phase 2b development for idiopathic pulmonary fibrosis and holding orphan drug designation in the European Union and the United States. The company is exploring additional rare diseases in which the AT2 receptor plays a key role. It is based in Mölndal, Sweden, in AstraZeneca’s Bioventurehub, and, in addition to its drug program, is pursuing a digital therapeutic approach with Almee, an investigational medical device designed to address the psychological impact of living with pulmonary fibrosis.

Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies. Its lead drug candidate, NB-4746, inhibits the SARM1 protein to prevent nerve damage in neurological diseases. The company aims to advance this therapy towards phase 1b/2 trials by 2025.

AnaptysBio is a clinical-stage biotechnology company focused on developing therapeutic antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes immune cell modulating antibodies such as rosnilimab, a PD-1 agonist in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in Phase 2b trial for atopic dermatitis.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Inhibrx, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company's focus areas include oncology, orphan diseases, and infectious diseases, employing advanced protein engineering techniques, including its proprietary sdAb platform. Among its leading candidates is INBRX-109, a multivalent agonist of death receptor 5, currently in Phase 1 trials for treating solid tumors, including sarcomas. Another candidate, INBRX-105, serves as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB, also in Phase 1 trials for PD-L1 expressing tumors. Additional candidates include INBRX-101, aimed at alpha-1 antitrypsin deficiency, and INBRX-103, targeting cluster of differentiation 47. The company's preclinical programs encompass innovative therapies such as INBRX-106, a hexavalent agonist of OX40, and INBRX-111, a multifunctional antibody targeting Pseudomonas aeruginosa. Founded in 2010, Inhibrx has established collaborations with prominent organizations and received funding from various granting agencies.

Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Mirati Therapeutics is a clinical-stage biotechnology company focused on developing cancer therapies. It concentrates on oncology, pursuing product candidates that address the genetic and immunological drivers of cancer. The company’s pipeline includes MRTX849, a KRAS G12C inhibitor in early-stage trials for non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other tumors, and sitravatinib, a spectrum-selective kinase inhibitor in Phase II for non-small cell lung cancer, along with a KRAS G12D inhibitor program in preclinical development. Mirati collaborates with BeiGene to develop and commercialize sitravatinib and maintains a clinical collaboration with Novartis. Founded in 1995 and headquartered in San Diego, Mirati aims to translate insights into therapies that address high unmet medical needs in oncology.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, focused on developing and commercializing innovative therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031 teplizumab, which is in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor currently in Phase IIa trials for Crohn's disease. Additional candidates include PRV-3279 for lupus, PRV-101, a vaccine for coxsackie virus B infections, and PRV-015, an anti-IL-15 monoclonal antibody in Phase IIb trials for non-responsive celiac disease. Provention Bio's approach aims to reduce the burden of chronic autoimmune and inflammatory diseases through early intervention. The company was incorporated in 2016 and is committed to leveraging its expertise in translational medicine and immunology to efficiently develop and partner with clinical-stage assets.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, focused on developing and commercializing innovative therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031 teplizumab, which is in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor currently in Phase IIa trials for Crohn's disease. Additional candidates include PRV-3279 for lupus, PRV-101, a vaccine for coxsackie virus B infections, and PRV-015, an anti-IL-15 monoclonal antibody in Phase IIb trials for non-responsive celiac disease. Provention Bio's approach aims to reduce the burden of chronic autoimmune and inflammatory diseases through early intervention. The company was incorporated in 2016 and is committed to leveraging its expertise in translational medicine and immunology to efficiently develop and partner with clinical-stage assets.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

Matchpoint Therapeutics is a biotechnology company focused on developing precision covalent medicines aimed at transforming the treatment of immune diseases and other serious illnesses. Utilizing its proprietary Advanced Covalent Exploration (ACE) platform, the company combines advanced chemoproteomics, machine learning, and the evolution of covalent chemistry libraries to enhance the discovery process. This innovative approach allows for deeper probing of the proteome to identify new binding sites on disease-causing proteins. Matchpoint is building an emerging pipeline of novel covalent medicines, with an initial emphasis on immunology.

Innovent Biologics is a China-based biopharmaceutical company that discovers, develops, manufactures, and commercializes monoclonal antibodies. It operates a platform for antibody therapeutics across oncology, ophthalmology, immunology, and metabolic diseases, with Tyvyt (sintilimab) as its core asset, a PD-1 inhibitor used in first-line and other cancer indications. The company develops a broad pipeline including biosimilars and novel antibodies and provides distribution, consulting, and R&D services. It maintains strategic collaborations with global partners, including a co-development arrangement with MD Anderson Cancer Center and an alliance with Eli Lilly for TYVYT, and has more than 30 collaborations with major pharmaceutical companies. Innovent is listed on the Hong Kong Exchange and maintains manufacturing and development capabilities in China with a growing portfolio of oncology and non-oncology products marketed domestically and internationally.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Nucleai Ltd. is a spatial biology company based in Tel Aviv-Yafo, Israel, founded in 2017. It has developed an AI-powered pathology platform that enhances drug development and improves patient outcomes by analyzing tissue datasets to provide insights into cancer biology. The platform is designed to detect various diseases, including cancer, prostate, breast, and gastrointestinal conditions, through advanced machine learning and computer vision techniques. By improving the interpretation of biopsies and supporting treatment decisions, Nucleai aims to increase the efficacy of clinical trials and enhance patient care. The company collaborates with leading pharmaceutical firms, licensing its technology for internal research and participating in biomarker discovery projects. Nucleai serves hospitals and laboratories primarily in the United States and Israel.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Kadmon Holdings is a biopharmaceutical company focused on discovering, developing, and commercializing small molecules and biologics for the treatment of inflammatory and fibrotic diseases. Founded in 2010 and headquartered in New York, Kadmon's lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of rho-associated coiled-coil kinase 2, which is in Phase II clinical trials for chronic graft-versus-host disease and fibrotic diseases; KD045, an oral inhibitor of ROCK for fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for cancer treatment. The company also develops Tesevatinib for autosomal dominant polycystic kidney disease, ribavirin for hepatitis, and CLOVIQUE for Wilson’s disease. Kadmon has strategic collaborations with Nano Terra and Dyax Corp.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Tidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Novadiscovery SAS, based in Lyon, France, specializes in the development of Jinko, an in silico clinical trial simulation platform. Established in 2010, the company aims to support pharmaceutical and biotech firms in conducting virtual trials, allowing for the prediction of clinical benefits of new drugs prior to human testing. The platform is particularly focused on areas such as immuno-oncology, orphan diseases, metabolic diseases, and cardiotherapy. By leveraging advanced mathematics and intelligent algorithms, Jinko creates a virtual patient community that serves as digital lab rats, enabling researchers to optimize drug development, assess efficacy, and reduce associated costs.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

Founded in 2016 and headquartered in Utrecht, the Netherlands, Lava Therapeutics is a biotechnology company specializing in the development of proprietary Vγ9Vδ2 T-cell engagers for immune oncology. Its platform focuses on creating bispecific antibodies to engage gamma-delta T cells for treating hematological and solid cancers.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Principia Biopharma Inc. is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead product, rilzabrutinib, is an inhibitor undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 trials for immune thrombocytopenia and Phase 2 trials for IgG4-related disease. Additionally, Principia is developing PRN2246/SAR442168, which is in Phase II for multiple sclerosis and other central nervous system conditions, alongside PRN473, a drug candidate in Phase I trials for immune-mediated diseases. Principia Biopharma maintains a collaboration agreement with Genzyme Corporation for the development of treatments for MS and other CNS diseases. Originally incorporated in 2008, the company is dedicated to addressing significant unmet medical needs in immunology and oncology through its innovative drug development platform.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

Synthorx, Inc. is a biopharmaceutical company specializing in the development of innovative protein therapeutics using advanced synthetic biology techniques. Founded in 2014 and headquartered in La Jolla, California, Synthorx focuses on its proprietary Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead product candidate, THOR-707, is a modified form of recombinant human IL-2, currently being evaluated for various solid tumors both as a standalone treatment and in combination with immune checkpoint inhibitors. The company also develops Synthorins targeting IL-2 for autoimmune conditions, IL-10 for immuno-oncology applications, and IL-15 for regulating immune responses. Synthorx leverages a unique platform that enables the incorporation of synthetic DNA base pairs to enhance the specificity and efficacy of its protein therapeutics, thus offering improved treatment options for patients. Previously known as Alinos, Inc., the company acquired exclusive rights to its synthetic biology technology based on groundbreaking research from The Scripps Research Institute. As of January 2020, Synthorx operates as a subsidiary of Sanofi.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

BioNTech is a Germany-based biotechnology company focused on developing cancer therapeutics and vaccines for infectious diseases. Its portfolio includes mRNA-based therapies to encode antigens and neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. The company maintains an oncology pipeline and collaborates on vaccines for infectious diseases, including a COVID-19 vaccine developed with Pfizer.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.

Ablynx is a biopharmaceutical company focused on discovering and developing Nanobodies®, a unique class of therapeutic proteins derived from single-domain antibody fragments. These Nanobodies are designed to treat serious human diseases, including inflammation, hematology, oncology, and pulmonary conditions. The company currently has around 25 projects in its pipeline, with five Nanobodies in clinical development. Ablynx's products aim to combine the advantages of conventional antibodies and small chemical molecules, offering patients innovative therapeutic options that can significantly impact society.

Bioverativ Inc. is a biopharmaceutical company focused on developing therapies for hemophilia and other rare blood disorders, including cold agglutinin disease, sickle cell disease, and beta thalassemia. Founded in 2016 and headquartered in Waltham, Massachusetts, the company aims to transform the lives of patients through innovative research and development. Bioverativ's pipeline features hemophilia therapies that offer less-frequent prophylactic dosing for hemophilia A and subcutaneous dosing for hemophilia B, as well as gene therapy programs for both types of hemophilia. Additionally, the company is working on Sutimlimab, a treatment aimed at inhibiting the complement pathway of the immune system to address cold agglutinin disease. As a subsidiary of Sanofi, Bioverativ continues to advance its mission to provide effective treatments for chronic blood disorders.

Thermalin, Inc. is a biotechnology company based in Cleveland, Ohio, founded in 2010, that focuses on developing innovative insulin therapies for individuals with Type 1 and Type 2 diabetes. The company aims to transform the insulin and insulin delivery market, valued at $30 billion, through its cutting-edge, highly concentrated, ultra-rapid acting insulin and a novel glucose management system that is the size of a postage stamp. This insulin can also be utilized in existing insulin pumps, enhancing their efficiency. In addition to its lead program, Thermalin is exploring partnerships to create no-cold-chain basal and mix insulins, as well as glucose-responsive insulins. Its products are designed to be rapidly absorbing and do not require refrigeration, thereby reducing the burden of insulin therapy and improving patient adherence and health outcomes.

Neurovia, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing therapies for neurological disorders, specifically targeting unmet medical needs in conditions such as X-linked adrenoleukodystrophy (X-ALD). Neurovia has created a selective thyromimetic agent aimed at treating X-ALD, a rare genetic disease that can lead to severe neurological deficits. By addressing these critical health challenges, Neurovia aims to improve the quality of life for patients affected by this condition.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Navitor Pharmaceuticals is a biopharmaceutical company developing targeted therapies for various diseases by modulating mTORC1 activity. Founded in 2009, the company is headquartered in Cambridge, Massachusetts.

Proteostasis Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies that regulate the body's protein homeostasis network to treat cystic fibrosis and other genetic or degenerative diseases. It develops Proteostasis Regulators intended to restore proteostasis balance and address conditions such as cystic fibrosis, emphysema, diabetes, and neurodegenerative disorders. In CF, its lead candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. The company collaborates with the Cystic Fibrosis Foundation to research, develop, and commercialize CF-related products, and has licensing relationships with Genentech. It was founded in 2006, formerly known as Proteoguard, and was renamed Proteostasis Therapeutics in 2007, based in Boston. It was acquired by Yumanity Therapeutics in 2020 in a reverse merger.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Ovid Therapeutics is a biopharmaceutical company focused on developing impactful medicines for patients with neurological disorders. Established in 2014, the company's pipeline includes OV101 (in Phase III for Angelman syndrome), OV935 (in Phase II for CDKL5 deficiency disorder and Dravet syndrome), and other programs targeting rare epilepsies and seizure-related disorders.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, specializing in the discovery, development, and commercialization of targeted therapies for rare cardiovascular diseases. Founded in 2012, the company focuses on heritable cardiomyopathies and genetically-driven heart failure stemming from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, which has completed Phase I and IIa trials for dilated cardiomyopathy, alongside several preclinical programs targeting related cardiovascular conditions. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Immune Design Corp., a clinical-stage immunotherapy company based in Seattle, Washington, focuses on enabling the body's immune system to combat diseases, with a primary emphasis on cancer treatment. The company leverages its ZVex and GLAAS discovery platforms to develop innovative therapies. Its lead product candidate is G100, currently in Phase II clinical trials for treating follicular non-Hodgkin lymphoma, both as a monotherapy and in combination therapy. Immune Design has collaboration and license agreements with Sanofi Pasteur. The company was founded in 2008 and operates under the umbrella of Merck & Co., Inc.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Edimer Pharmaceuticals is a biotechnology company focused on developing innovative treatments for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as the absence of sweat glands, impaired temperature regulation, respiratory issues, and malformations of hair and teeth. The company's lead product candidate, EDI200, aims to provide significant and lasting improvements in health and quality of life for individuals affected by this condition. Edimer is guided by a team of experienced professionals in the biotechnology sector, supported by a network of distinguished clinical and scientific advisors, all committed to addressing the needs of families impacted by XLHED.

Lumena Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for rare liver diseases, particularly cholestatic liver disease. Its lead candidate, LUM001, targets a specific transporter in the intestine, which reduces the risk of systemic toxicities by being minimally absorbed in the body. LUM001 has been extensively studied across 12 clinical trials involving over 1,400 subjects, positioning it for rapid advancement in both pediatric and adult patients. While Lumena's primary objective is to provide novel treatments for rare liver diseases, its therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which are increasingly recognized as significant health concerns in both children and adults.

Pluromed, Inc., founded in 2003 and based in Woburn, Massachusetts, develops, manufactures, and markets disposable medical devices utilizing reverse thermosensitive polymer technology. The company's product portfolio includes the LeGoo Internal Vessel Occluder for temporary blood vessel occlusion, LeGoo Endovascular Occlusion Gel for clampless vascular and cardiovascular surgery, BackStop to prevent stone migration during ureteroscopic lithotripsy, and Lumagel for various cancer therapies and surgical procedures. These devices are designed to control bleeding during surgeries such as cardiac and vascular operations, plastic and reconstructive surgeries, kidney and liver cancer treatments, and trauma/battlefield injuries.

Esperance Pharmaceuticals Inc. is a biotechnology company focused on developing targeted anticancer drugs aimed primarily at treating ovarian and breast cancer in women. Founded in 2005 and based in Houston, Texas, the company is advancing its lead product, EP-100, an oncolytic peptide designed to selectively attack and destroy cancer cells that express luteinizing hormone releasing hormone (LHRH) receptors. This innovative approach enables the drug to kill cancer cells, including those resistant to traditional chemotherapeutics, while sparing normal cells. Esperance Pharmaceuticals has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, enhancing its potential impact in oncology.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Sanofi Genzyme is the specialty care global business unit of Sanofi, primarily dedicated to addressing the challenges posed by rare diseases, multiple sclerosis, immunology, and oncology. Established in 1981 as Genzyme in Boston, the company grew to become a major player in biotechnology, known for pioneering treatments for rare genetic disorders. In 2011, Genzyme was integrated into Sanofi, enhancing its capabilities in developing therapies for complex conditions that are often difficult to diagnose and treat. Sanofi Genzyme emphasizes a patient-centered approach, collaborating closely with healthcare providers and patient communities to advance new therapies. Over the years, its focus has expanded beyond rare diseases to include significant contributions in multiple sclerosis, oncology, and immunology, reflecting a commitment to innovation and improving patient outcomes across diverse therapeutic areas.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Shantha Biotechnics, founded in 1993 by Dr. Varaprasad Reddy and based in Hyderabad, India, focuses on the development, manufacturing, and marketing of vaccines. The company operates in a state-of-the-art facility that meets international standards and collaborates with organizations such as UNICEF and PAHO to supply vaccines to major markets across Asia-Pacific, Africa, and Latin America. Shantha is known for its pioneering work in vaccine production, having launched SHANVAC-B, the first recombinant Hepatitis B vaccine produced in India, in 1997. Its product portfolio includes SHANVAC-B, SHANTETRA (a combination vaccine for Diphtheria, Pertussis, Tetanus, and Hepatitis B), SHAN5 (a combination vaccine for Diphtheria, Pertussis, Tetanus, Haemophilus influenzae type B, and Hepatitis B), and SHANTT (a Tetanus toxoid vaccine), all of which are prequalified by the World Health Organization for distribution to United Nations agencies. Additionally, Shantha is engaged in developing several vaccines to expand its offerings.

BiPar Sciences Inc. is a biotechnology company based in Brisbane, California, focused on developing innovative cancer therapies, particularly through the use of PARP inhibitors. Its lead product, BSI-201, is currently undergoing mid-stage clinical trials for advanced breast cancer, ovarian cancer, and other challenging tumors. BiPar's portfolio also includes candidates targeting therapy-resistant cancers and additional drug programs aimed at enhancing the efficacy of chemotherapy. The company has secured approximately $60 million in venture capital funding from various investors and has attracted venture debt to support its initiatives. In April 2009, BiPar Sciences was acquired by the French pharmaceutical company Sanofi-Aventis, indicating its potential significance in the oncology market.

Zentiva is a prominent generics company based in Europe, recognized as the third largest in the region and noted for its rapid growth. The company's roots trace back to the 15th century, reflecting a long-standing history in the pharmaceutical industry. Zentiva specializes in the manufacture of medicines and is actively involved in research and development to enhance its product offerings. As a valued partner in the generics market, Zentiva is dedicated to providing accessible and effective healthcare solutions.

Proteostasis Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies that regulate the body's protein homeostasis network to treat cystic fibrosis and other genetic or degenerative diseases. It develops Proteostasis Regulators intended to restore proteostasis balance and address conditions such as cystic fibrosis, emphysema, diabetes, and neurodegenerative disorders. In CF, its lead candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. The company collaborates with the Cystic Fibrosis Foundation to research, develop, and commercialize CF-related products, and has licensing relationships with Genentech. It was founded in 2006, formerly known as Proteoguard, and was renamed Proteostasis Therapeutics in 2007, based in Boston. It was acquired by Yumanity Therapeutics in 2020 in a reverse merger.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing therapeutics that restore the function of microglia, the brain's immune cells. The company aims to improve outcomes for patients with neurodegenerative diseases by advancing its lead monoclonal antibody TREM2 agonist through Phase 1 trials and progressing its small molecule TREM2 agonist towards an Investigational New Drug (IND) application.